EA200600400A1 - Новая композиция, содержащая росиглитазон и другое противодиабетическое средство - Google Patents

Новая композиция, содержащая росиглитазон и другое противодиабетическое средство

Info

Publication number
EA200600400A1
EA200600400A1 EA200600400A EA200600400A EA200600400A1 EA 200600400 A1 EA200600400 A1 EA 200600400A1 EA 200600400 A EA200600400 A EA 200600400A EA 200600400 A EA200600400 A EA 200600400A EA 200600400 A1 EA200600400 A1 EA 200600400A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetic
composition containing
new composition
containing rosiglitazone
rosiglitazone
Prior art date
Application number
EA200600400A
Other languages
English (en)
Other versions
EA011550B1 (ru
Inventor
Питер Джон Коулз
Дональд Колин Маккензи
Пол Норман мл. Мадд
Original Assignee
Эс Би ФАРМКО ПУЭРТО РИКО ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27840010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200600400(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эс Би ФАРМКО ПУЭРТО РИКО ИНК. filed Critical Эс Би ФАРМКО ПУЭРТО РИКО ИНК.
Publication of EA200600400A1 publication Critical patent/EA200600400A1/ru
Publication of EA011550B1 publication Critical patent/EA011550B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Abstract

Пероральная лекарственная форма, включающая эродируемое ядро, которое содержит росиглитазон или его фармацевтически приемлемую соль или сольват и другое противодиабетическое средство, при этом ядро имеет покрытие с одним или несколькими отверстиями, характеризующееся тем, что покрытие является эродируемым в заданных условиях рН; способ получения такой лекарственной формы и применение такой лекарственной формы в медицине.
EA200600400A 2003-08-11 2004-08-09 Композиция росиглитазона и метформина EA011550B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0318824.0A GB0318824D0 (en) 2003-08-11 2003-08-11 Novel composition
PCT/EP2004/008970 WO2005013956A1 (en) 2003-08-11 2004-08-09 Novel composition comprising rosiglitazone and another antidiabetic agent

Publications (2)

Publication Number Publication Date
EA200600400A1 true EA200600400A1 (ru) 2006-08-25
EA011550B1 EA011550B1 (ru) 2009-04-28

Family

ID=27840010

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200600400A EA011550B1 (ru) 2003-08-11 2004-08-09 Композиция росиглитазона и метформина
EA200800966A EA200800966A1 (ru) 2003-08-11 2004-08-09 Новая композиция, содержащая росиглитазон и другое противодиабетическое средство

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200800966A EA200800966A1 (ru) 2003-08-11 2004-08-09 Новая композиция, содержащая росиглитазон и другое противодиабетическое средство

Country Status (37)

Country Link
US (1) US20080206336A1 (ru)
EP (1) EP1663191B1 (ru)
JP (1) JP4714147B2 (ru)
KR (1) KR20060071396A (ru)
CN (2) CN102397551A (ru)
AP (1) AP2006003489A0 (ru)
AR (1) AR045230A1 (ru)
AT (1) ATE455542T1 (ru)
AU (1) AU2004262933B2 (ru)
BR (1) BRPI0413419A (ru)
CA (1) CA2534480A1 (ru)
CY (1) CY1109923T1 (ru)
DE (1) DE602004025257D1 (ru)
DK (1) DK1663191T3 (ru)
EA (2) EA011550B1 (ru)
EC (1) ECSP066338A (ru)
ES (1) ES2339554T3 (ru)
GB (1) GB0318824D0 (ru)
HK (1) HK1092051A1 (ru)
HR (1) HRP20100160T1 (ru)
IL (1) IL173177A0 (ru)
IS (1) IS2745B (ru)
MA (1) MA27996A1 (ru)
MX (1) MXPA06001629A (ru)
MY (1) MY151053A (ru)
NO (1) NO20061161L (ru)
NZ (1) NZ544632A (ru)
OA (1) OA13233A (ru)
PE (1) PE20050357A1 (ru)
PL (1) PL1663191T3 (ru)
PT (1) PT1663191E (ru)
SG (1) SG165178A1 (ru)
SI (1) SI1663191T1 (ru)
TW (1) TW200517146A (ru)
UA (1) UA82537C2 (ru)
UY (1) UY28461A1 (ru)
WO (1) WO2005013956A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
WO2010009433A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
WO2011161521A1 (en) * 2010-06-21 2011-12-29 Lupin Limited Compositions comprising metformin and rosiglitazone
CN103153288B (zh) * 2010-07-09 2017-02-15 詹姆斯·特林卡·格林 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
CN102727459A (zh) * 2011-04-15 2012-10-17 江苏豪森医药集团有限公司 一种具有第一和第二活性药物的制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
EP1067910B1 (en) * 1998-04-03 2004-05-26 Egalet A/S Controlled release composition
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
UA67802C2 (ru) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ ИНГИБИТОРА цГМФ ФДЭ-5 (ВАРИАНТЫ), СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СПОСОБ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ
ES2256927T3 (es) * 1998-11-10 2006-07-16 THE PROCTER & GAMBLE COMPANY Composiciones blanqueantes.
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
EP1813273A1 (en) * 1998-11-12 2007-08-01 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AU1403501A (en) * 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
CA2407713A1 (en) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. A core formulation
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Also Published As

Publication number Publication date
DK1663191T3 (da) 2010-04-26
AU2004262933B2 (en) 2009-12-10
US20080206336A1 (en) 2008-08-28
PE20050357A1 (es) 2005-06-01
JP2007501830A (ja) 2007-02-01
ES2339554T3 (es) 2010-05-21
AR045230A1 (es) 2005-10-19
DE602004025257D1 (de) 2010-03-11
MA27996A1 (fr) 2006-07-03
CN1835741A (zh) 2006-09-20
NO20061161L (no) 2006-03-10
GB0318824D0 (en) 2003-09-10
NZ544632A (en) 2009-03-31
AP2006003489A0 (en) 2006-02-28
JP4714147B2 (ja) 2011-06-29
CN1835741B (zh) 2011-12-14
SI1663191T1 (sl) 2010-05-31
KR20060071396A (ko) 2006-06-26
UY28461A1 (es) 2005-03-31
IL173177A0 (en) 2006-06-11
MY151053A (en) 2014-03-31
CN102397551A (zh) 2012-04-04
ATE455542T1 (de) 2010-02-15
IS8337A (is) 2006-03-02
PT1663191E (pt) 2010-03-16
AU2004262933A1 (en) 2005-02-17
EA200800966A1 (ru) 2009-04-28
HK1092051A1 (en) 2007-02-02
HRP20100160T1 (hr) 2010-05-31
ECSP066338A (es) 2006-07-28
CY1109923T1 (el) 2014-09-10
IS2745B (is) 2011-08-15
TW200517146A (en) 2005-06-01
PL1663191T3 (pl) 2010-06-30
CA2534480A1 (en) 2005-02-17
EP1663191B1 (en) 2010-01-20
WO2005013956A1 (en) 2005-02-17
MXPA06001629A (es) 2006-04-28
OA13233A (en) 2006-12-13
BRPI0413419A (pt) 2006-10-10
SG165178A1 (en) 2010-10-28
UA82537C2 (ru) 2008-04-25
EA011550B1 (ru) 2009-04-28
EP1663191A1 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
UY27175A1 (es) Nueva sal succinato de o-desmetil- venlafaxina
CY1109923T1 (el) Νεα συνθεση που περιεχει ροσιγλιταζονη κι ενα αλλο αντιδιαβητικο μεσο
IS7142A (is) Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
BRPI0409652A (pt) tablete, embalagem farmacêutica, método de tratamento de doenças, e, método de preparação de um tablete
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
ECSP055738A (es) PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL
EA200300999A1 (ru) Хронотерапевтические дозированные формы
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
NO20016346D0 (no) Ny formulering
HUP0302553A2 (hu) Egy izotiazol-4-karbonsavamid sói és eljárás az előállításukra és ezek alkalmazására a túlzott mértékű sejtburjánzás visszaszorítására alkalmas gyógyszerkészítmények előállítására
SE9700885D0 (sv) New pharmaceutical formulation
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
NO20051261L (no) Morfin-6-glukuronidsalt
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
EA200701409A1 (ru) Новая композиция
EA200401071A1 (ru) Пероральная лекарственная форма для контролируемого высвобождения лекарственного средства
SE0202365D0 (sv) New formulation and use thereof
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine
IL151815A0 (en) Drug combination for the treatment of headache comprising a non-steroidal anti-inflammatory drug
NO975790L (no) Anvendelse av allylaminderivater slik som terbinafin, i fremstillingen av et medikament for behandling av helikobacterpylori-infeksjonsassosierte sykdommer

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU